Gabriel S. Morris, CFO and President of Immix Biopharma, Inc. (NASDAQ:IMMX), filed a Form 4 on November 20, 2026, disclosing a purchase of common stock on November 18, 2026.
Key Highlights
- Purchase transaction: Morris acquired 1,418 shares of Immix Biopharma common stock on November 18, 2026, at a price of $7.06 per share.
- Direct ownership after transaction: Following the purchase, Morris directly holds 292,847 shares of common stock.
- Indirect holdings via Alwaysraise LLC: Morris also beneficially owns 426,844 shares indirectly through Alwaysraise LLC, of which he is Managing Partner and Sole Member.
- Indirect holdings via AVILP: An additional 24,141 shares are held indirectly through Alwaysraise Ventures I, LP, for which Morris serves as Managing Partner of the general partner entity.
- Dual role: The filing identifies Morris as both a Director and an Officer, holding the titles of CFO and President.
Morris's November 18 Open-Market Purchase and Beneficial Ownership at Immix Biopharma
According to the filing, Gabriel S. Morris, who serves as CFO, President, and Director of Immix Biopharma, Inc., purchased 1,418 shares of the company's common stock on November 18, 2026, at $7.06 per share. The transaction code reported is "P," indicating an open-market purchase. Following this acquisition, the filing reports that Morris directly holds 292,847 shares of common stock.
In addition to his direct holdings, the filing discloses two categories of indirect beneficial ownership. Morris holds 426,844 shares indirectly through Alwaysraise LLC, an entity for which he is Managing Partner and Sole Member, giving him the right to vote and dispose of those securities. He also holds 24,141 shares indirectly through Alwaysraise Ventures I, LP (AVILP), where he is Managing Partner of the general partner, Alwaysraise Ventures I Investments, LLC. The filing notes that Morris "disclaims beneficial ownership of the securities reported herein as held by Alwaysraise, except to the extent of his pecuniary interest therein," and the same disclaimer applies to the securities held by AVILP.
No derivative securities transactions were reported in Table II of the filing. The Form 4 was signed by Gabriel Morris and filed on November 20, 2026, covering the earliest transaction date of November 18, 2026.
What Was Disclosed
The filing disclosed a direct open-market purchase of 1,418 shares of Immix Biopharma common stock at $7.06 per share by CFO and President Gabriel S. Morris on November 18, 2026, along with his total direct and indirect beneficial ownership positions following the transaction.




Please wait processing your request...